Chengdu Kanghong Pharmaceuticals Group Co., Ltd engages in the research, development, production, and sale of biological products, Chinese medicines, and chemical drugs in China.
Chengdu Kanghong Pharmaceutical Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CN¥18.42|
|52 Week High||CN¥17.63|
|52 Week Low||CN¥49.20|
|1 Month Change||-0.65%|
|3 Month Change||-7.85%|
|1 Year Change||-56.07%|
|3 Year Change||-41.51%|
|5 Year Change||-55.92%|
|Change since IPO||83.17%|
Recent News & Updates
|2773||CN Pharmaceuticals||CN Market|
Return vs Industry: 002773 underperformed the CN Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: 002773 underperformed the CN Market which returned 7.2% over the past year.
Stable Share Price: 002773 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 002773's weekly volatility (4%) has been stable over the past year.
About the Company
Chengdu Kanghong Pharmaceuticals Group Co., Ltd engages in the research, development, production, and sale of biological products, Chinese medicines, and chemical drugs in China. It offers ophthalmic systems, central nervous systems, digestive systems, and other system drugs. The company was founded in 1996 and is headquartered in Chengdu, China.
Chengdu Kanghong Pharmaceutical Group Fundamentals Summary
|2773 fundamental statistics|
Is 2773 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2773 income statement (TTM)|
|Cost of Revenue||CN¥379.21m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.20|
|Net Profit Margin||-4.84%|
How did 2773 perform over the long term?See historical performance and comparison
0.5%Current Dividend Yield
Is Chengdu Kanghong Pharmaceutical Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: 002773 (CN¥18.42) is trading above our estimate of fair value (CN¥9.05)
Significantly Below Fair Value: 002773 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 002773 is unprofitable, so we can't compare its PE Ratio to the CN Pharmaceuticals industry average.
PE vs Market: 002773 is unprofitable, so we can't compare its PE Ratio to the CN market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 002773's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 002773 is overvalued based on its PB Ratio (2.8x) compared to the CN Pharmaceuticals industry average (2.6x).
How is Chengdu Kanghong Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 002773 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.3%).
Earnings vs Market: 002773 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 002773's is expected to become profitable in the next 3 years.
Revenue vs Market: 002773's revenue (17.6% per year) is forecast to grow slower than the CN market (18.4% per year).
High Growth Revenue: 002773's revenue (17.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 002773's Return on Equity is forecast to be high in 3 years time
How has Chengdu Kanghong Pharmaceutical Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 002773 is currently unprofitable.
Growing Profit Margin: 002773 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 002773 is unprofitable, and losses have increased over the past 5 years at a rate of 13.6% per year.
Accelerating Growth: Unable to compare 002773's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 002773 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.6%).
Return on Equity
High ROE: 002773 has a negative Return on Equity (-3.02%), as it is currently unprofitable.
How is Chengdu Kanghong Pharmaceutical Group's financial position?
Financial Position Analysis
Short Term Liabilities: 002773's short term assets (CN¥3.6B) exceed its short term liabilities (CN¥533.1M).
Long Term Liabilities: 002773's short term assets (CN¥3.6B) exceed its long term liabilities (CN¥230.4M).
Debt to Equity History and Analysis
Debt Level: 002773 is debt free.
Reducing Debt: 002773 had no debt 5 years ago.
Debt Coverage: 002773 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 002773 has no debt, therefore coverage of interest payments is not a concern.
What is Chengdu Kanghong Pharmaceutical Group current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 002773's dividend (0.54%) is higher than the bottom 25% of dividend payers in the CN market (0.42%).
High Dividend: 002773's dividend (0.54%) is low compared to the top 25% of dividend payers in the CN market (1.86%).
Stability and Growth of Payments
Stable Dividend: 002773 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 002773 has only been paying a dividend for 5 years, and since then payments have fallen.
Current Payout to Shareholders
Dividend Coverage: 002773 is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Xiao Ke (38 yo)
Mr. Xiao Ke serves as a General Manager and President of Chengdu Kanghong Pharmaceuticals Group Co., Ltd., and Director since June 21, 2010 and served as Vice President.
Experienced Board: 002773's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.3%.
Chengdu Kanghong Pharmaceutical Group Co., Ltd's employee growth, exchange listings and data sources
- Name: Chengdu Kanghong Pharmaceutical Group Co., Ltd
- Ticker: 2773
- Exchange: SZSE
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥17.010b
- Shares outstanding: 919.46m
- Website: https://www.cnkh.com
Number of Employees
- Chengdu Kanghong Pharmaceutical Group Co., Ltd
- No.36, Shuxi Road
- Jinniu District
- Sichuan Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 09:03|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.